文献速递药物不良反应与药物警戒抗栓抗凝管理肝肾功能剂量调整

华法林与直接口服抗凝药相关肾病的危险因素差异:日本不良药物事件报告数据库分析

Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-18

本研究基于日本不良药物事件报告数据库,分析华法林或直接口服抗凝药(DOAC)使用者中肾损伤(KI)的发生情况,并探讨抗凝药相关肾病(ARN)的危险因素。结果显示,华法林使用者KI风险与男性及年龄≥80岁相关,DOAC使用者KI风险与体重≥80 kg及使用达比加群相关。提示两类抗凝药的ARN危险因素不同,且可能与出血风险相关,优化出血风险管理或可降低ARN风险。

要点

  • 华法林使用者肾损伤风险与男性(OR 1.70)和年龄≥80岁(OR 1.35)相关。
  • DOAC使用者肾损伤风险与体重≥80 kg(OR 1.60)和使用达比加群(OR 1.61)相关。
  • 华法林与DOAC的ARN危险因素不同,且可能与出血风险相关。

核心结论

  • 华法林与DOAC相关肾损伤的危险因素存在差异,这些因素可能与出血风险相关,优化出血风险管理或可降低ARN风险。

研究设计与样本

  • 基于日本不良药物事件报告数据库的回顾性分析,纳入使用华法林或DOAC并发生肾损伤的患者。

临床怎么用

  • 临床使用华法林时应关注男性和高龄(≥80岁)患者的肾损伤风险。
  • 临床使用DOAC时应关注体重≥80 kg及使用达比加群患者的肾损伤风险,并加强出血风险管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limited information is available on anticoagulant-related nephropathy (ARN). We therefore reviewed the Japanese Adverse Drug Event Report database to investigate kidney injury (KI) in patients administered warfarin or direct oral anticoagulants (DOACs) and sought to clarify the risk factors for ARN. KI risk in warfarin users was associated with male sex (odds ratio [OR], 1.70; 95% confidence interval [CI], 1.35-2.13; P < .01) and age ≥80 years (OR, 1.35; 95% CI, 1.07-1.72; P = .01). KI risk in DOAC users was associated with body weight ≥80 kg (OR, 1.60; 95% CI, 1.01-2.53; P = .04) and use of dabigatran (OR, 1.61; 95% CI, 1.09-2.37; P < .01). Our findings suggest that risk factors for ARN differ between warfarin and DOACs and that these risk factors may be associated with bleeding risk. Therefore, the risk of ARN may be decreased by better managing bleeding risk in patients taking anticoagulants.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Mitsuboshi S, Niimura T, Zamami Y, et al. Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database. Br J Clin Pharmacol. 2020. PMID: 33270271. doi:10.1111/bcp.14688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。